VivoSeq
Ophthalmology

Retinal Artery Occlusion

5

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Retinal Artery Occlusion is an early-stage landscape with 5 programs across 2 companies. The most active players are Roche, Bayer. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

0/100

Mech. Concentration

67/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 3Bayer logo

Bayer

2 programs

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

60%

Small molecule

3 of 5 classified programs — the dominant modality here.

40%ALL OTHERSProtein / enzyme240%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Recruiting1 · 25%

Clinical Trials

Trial Activity

A Study of the Efficacy and Safety of KUS121 in Participants With Acute Non-Arteritic Central Retinal Artery Occlusion (CRAO)
Completed·KKyoto Drug Discovery and Development Co., Ltd.·Phase 2·NCT06178055·17 enrolled
A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion
Completed·NNantes University Hospital·Phase 3·NCT03197194·70 enrolled
TENecteplase in Central Retinal Artery Occlusion Stuy (TenCRAOS)
Completed·OOslo University Hospital·Phase 3·NCT04526951·81 enrolled
Early Reperfusion Therapy With Intravenous Thrombolysis for Recovery of VISION in Acute Central Retinal Artery Occlusion
Recruiting·UUniversity Hospital Tuebingen·Phase 3·NCT04965038·422 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)